Want to see PRME full AI Analyst Report?
Compare Prime Medicine, Inc. (PRME) vs. Competitors
Comparison Results
| Name | Price | Market Cap | P/E Ratio | Yearly Gain | Analyst Consensus | Analyst Price Target | Compare | Top Analysts' Price Target | Smart Score | Follow |
|---|---|---|---|---|---|---|---|---|---|---|
| PRMEPrime Medicine, Inc. | $4.72 | $856.10M | -4.29 | 8.51% | Strong Buy | PRME | ||||
| IMTXImmatics | $7.20 | $1.08B | -4.04 | -30.90% | Strong Buy | PRME vs IMTX | ||||
| RLAYRelay Therapeutics | $18.35 | $4.02B | -11.69 | 150.00% | Strong Buy | PRME vs RLAY | ||||
| TSHATaysha Gene Therapies | $4.13 | $1.35B | -9.77 | -15.89% | Strong Buy | PRME vs TSHA | ||||
| SANASana Biotechnology | $2.57 | $769.36M | -3.38 | -47.55% | Strong Buy | PRME vs SANA | ||||
| UPBUpstream Bio, Inc. | $3.41 | $186.77M | -1.18 | -86.77% | Strong Buy | PRME vs UPB |
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PRME | Prime Medicine, Inc. | 4.72 | 0.16 | 3.51% | |
| IMTX | Immatics | 7.20 | -2.48 | -25.62% | |
| RLAY | Relay Therapeutics | 18.35 | 11.41 | 164.41% | |
| TSHA | Taysha Gene Therapies | 4.13 | -0.33 | -7.40% | |
| SANA | Sana Biotechnology | 2.57 | -2.00 | -43.76% | |
| UPB | Upstream Bio, Inc. | 3.41 | -21.61 | -86.37% |
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts